Conclusion
PsA, RA, rheumatic diseases
RHEUMATIC DISEASES
This post-hoc analysis of data collected prospectively from five Phase III clinical trials of golimumab in participants with rheumatic diseases presents, for the first time, comparative persistence results using Kaplan–Meier analysis. High treatment retention was seen across indications (RA, PsA, and AS), with at least two-thirds of patients estimated to remain on therapy five years after treatment initiation. Probability of long-term golimumab treatment retention with 2